Expression of bone turnover markers in patients with tuboovarian carcinoma exposed to platinum-based chemotherapy ± bevacizumab

被引：0
|
作者：
Kurbacher, C. M. [1 ]
Huhmann, A. [1 ]
Herz, S. [1 ]
Kurbacher, A. T. [1 ]
Monreal, K. [1 ]
Kurbacher, J. A. [2 ]
机构：
[1] Gynecol Ctr Bonn Friedenspl, Gynecol Oncol, Bonn, Germany
[2] Gynecol Ctr Bonn Friedenspl, Gen Gynecol & Obstet, Bonn, Germany
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2016年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS-0268
引用
收藏
页码：750 / 750
页数：1
相关论文
共 50 条
  • [31] Phase II Study of Temozolomide Monotherapy in Patients of Neuroendocrine Carcinoma with Resistant to Platinum-Based Chemotherapy
    Ichikawa, Y.
    Kobayashi, N.
    Tokuhisa, M.
    Goto, A.
    Hiroshima, Y.
    NEUROENDOCRINOLOGY, 2018, 106 : 196 - 196
  • [32] Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
    Furubayashi, Nobuki
    Hori, Yoshifumi
    Morokuma, Futoshi
    Tomoda, Toshihisa
    Negishi, Takahito
    Inoue, Tomohiro
    Kumagai, Masatoshi
    Kuroiwa, Kentaro
    Tokuda, Noriaki
    Nakamura, Motonobu
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (05)
  • [33] Modification of Platinum-based Systemic Chemotherapy for Advanced Urothelial Carcinoma in Patients With Suboptimal Renal Function
    Hamada, Akihiro
    Sano, Takeshi
    Matsumoto, Keiyu
    Sakatani, Toru
    Nakamura, Kenji
    Sawada, Atsuro
    Akamatsu, Shusuke
    Matsui, Yoshiyuki
    Ogawa, Osamu
    Kobayashi, Takashi
    IN VIVO, 2021, 35 (05): : 2821 - 2829
  • [34] Can metallothionein be a useful molecular marker for selecting hepatocellular carcinoma patients for platinum-based chemotherapy?
    Yuichiro Doki
    Morito Monden
    Journal of Gastroenterology, 2004, 39 : 1228 - 1229
  • [35] Can metallothionein be a useful molecular marker for selecting hepatocellular carcinoma patients for platinum-based chemotherapy?
    Doki, Y
    Monden, M
    JOURNAL OF GASTROENTEROLOGY, 2004, 39 (12) : 1228 - 1229
  • [36] Efficacy of eribulin therapy in patients with advanced adenoid cystic carcinoma receiving platinum-based chemotherapy
    Sanomachi, T.
    Shimoi, T.
    Kojima, Y.
    Kawachi, A.
    Okuma, H. Sumiyoshi
    Hoshino, M.
    Ito, M.
    Saito, A.
    Kita, S.
    Maejima, A.
    Nishikawa, T.
    Sudo, K.
    Mori, T.
    Yonemori, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1319 - S1319
  • [37] Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel
    Vaidya, AP
    Littell, R
    Krasner, C
    Duska, LR
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 : 267 - 272
  • [38] Pathological predictors of the response to platinum-based chemotherapy in pancreatobiliary neuroendocrine carcinoma
    Furukawa, Takaaki
    Ozaka, Masato
    Takamatsu, Manabu
    Okamoto, Takeshi
    Ishitsuka, Takahiro
    Yamada, Manabu
    Nakagawa, Hiroki
    Mie, Takafumi
    Takeda, Tsuyoshi
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Sasaki, Takashi
    Sasahira, Naoki
    ANNALS OF ONCOLOGY, 2023, 34 : S1438 - S1438
  • [39] The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma
    Zanotti, KM
    Belinson, JL
    Kennedy, AW
    Webster, KD
    Markman, M
    GYNECOLOGIC ONCOLOGY, 1999, 74 (02) : 272 - 277
  • [40] THE ASSOCIATION BETWEEN EXPRESSION OF TBX2 AND SENSITIVITY TO PLATINUM-BASED CHEMOTHERAPY FOR OVARIAN SEROUS CARCINOMA
    Tasaka, R.
    Fukuda, T.
    Inoue, Y.
    Shimomura, M.
    Matsubara, H.
    Wada, T.
    Kawanishi, M.
    Yasui, T.
    Sumi, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1494 - 1494
12345